Changes in post-treatment cardiac PET avidity predict overall survival in lung cancer patients treated with chemoradiation: Secondary analysis of the ACRIN 6668/RTOG 0235 clinical trial

Ryan Miller, Tess Santangelo, Farnoush Forghani-Arani, Chad Rusthoven, Yingxuan Chen, Edward Castillo, Richard Castillo, Thomas Guerrero, Yevgeniy Vinogradskiy

Research output: Contribution to journalArticlepeer-review

Abstract

The purpose of this work was to use data from a large co-operative group trial to evaluate whether metabolic FDG-PET changes in the heart for lung cancer patients can predict for clinical outcomes. The study found that cardiac SUV changes following definitive chemoradiation are significantly (HR 0.811, 95% CI 0.68–0.96, p = 0.017) associated with overall survival in locally advanced NSCLC patients. If validated in a prospective cohort, our data show the potential for cardiac metabolic changes to be an early predictor for clinical outcomes.

Original languageEnglish
Pages (from-to)22-24
Number of pages3
JournalRadiotherapy and Oncology
Volume171
DOIs
StatePublished - Jun 2022

Keywords

  • Cardiac toxicity
  • Functional imaging
  • Lung cancer

Fingerprint

Dive into the research topics of 'Changes in post-treatment cardiac PET avidity predict overall survival in lung cancer patients treated with chemoradiation: Secondary analysis of the ACRIN 6668/RTOG 0235 clinical trial'. Together they form a unique fingerprint.

Cite this